Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer- Prospect Lung
- Sponsor:
- Alliance for Clinical Trials in Oncology
- Sponsor Study ID:
- CTIU2317-A082304-S2402
- CTO #:
- 104171
- NCT Number:
- NCT06632327
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- To compare the 3-year real-world event-free survival (rwEFS) rate and overall survival (OS) between perioperative and adjuvant immunotherapy-based treatment for patients with resectable non-small cell lung cancer (dual endpoints).
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Gibney, Barry, at gibney@musc.edu .
- Study Coordinator, Schumpp, Alec, at schumpp@musc.edu .
-
Self Regional Medical Center
- Affiliate Principal Investigator, Metzner-Sadurski, Joanna, at jsadurski@selfregional.org .
- Study Coordinator, Blalock, Margaret, at margaret.bentley@selfregional.org .
- Study Coordinator, Nelson, Kristina, at knelson@selfregional.org .
Trial opened at the following institutions:
Self Regional Medical Center, Medical University of South Carolina